Silver Book Fact

TAVR Success in sSAS Patients

A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable, and 1.1% for those at intermediate surgical mortality risk.

Kodali S, Thourani V, White J, Malaisrie S, et al. Early Clinical and Echocardiographic Outcomes After SAPIEN 3 Transcatheter Aortic Valve Replacement in Inoperable, High-Risk and Intermediate-Risk Patients with Aortic Stenosis. Eur Heart J. 2016; 37: 2252-62. https://academic.oup.com/eurheartj/article/37/28/2252/2237654/Early-clinical-and-echocardiographic-outcomes

Reference

Title
Early Clinical and Echocardiographic Outcomes After SAPIEN 3 Transcatheter Aortic Valve Replacement in Inoperable, High-Risk and Intermediate-Risk Patients with Aortic Stenosis
Publication
Eur Heart J
Publication Date
2016
Authors
Kodali S, Thourani V, White J, Malaisrie S, et al.
Pages
2252-62
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • Survival Rates of SAS Patients with and without SAVR
    Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
  • Survival rates of SAS patients ages 80+ with and without SAVR
     
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…